Smoking and Activated Clotting Time During Coronary Angiography and Angioplasty: Protocol for the ACT-Tobacco Trial

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2023 Mar 14

PMID 36915865

Authors

Regis Trimole

Hugo Manzi

Kossar Hosseini

Thomas Remen

Marie Toussaint-Hacquard

Edoardo Camenzind

Affiliations

Soon will be listed here.

Abstract

Background: During percutaneous transluminal coronary angioplasty (PTCA), activated clotting time (ACT) measurements are recommended to attest a correct anticoagulation level and, if needed, to administer further unfractionated heparin (UFH) to obtain a therapeutic ACT value. Our clinical routine led us to observe that smokers had lower ACT values after standardized UFH administration during PTCA. Procoagulant status in smokers is well documented.

Objectives: To determine whether tobacco negatively affects UFH anticoagulation during PTCA when evaluated by ACT.

Methods: The ACT-TOBACCO trial is a single-center, noninterventional, prospective study. The primary end point is the comparison of ACT values after standardized UFH administration between active smokers and nonsmokers (active smoker group vs nonsmoker group) requiring coronary angiography followed by PTCA. The main secondary end points include ACT comparison after the first and second standardized UFH administration according to the patient's smoking status (active, ex-, or nonsmoker) and the clinical presentation of ischemic cardiomyopathy: stable (silent ischemia or stable angina) or unstable (unstable angina or acute coronary syndrome without or with ST-segment elevation).

Conclusions: To the best of our knowledge, ACT values during PTCA between smokers and nonsmokers have not previously been compared. As current PTCA procedures increase in complexity and duration, the understanding of procoagulant risk factors such as smoking and the need for reliable anticoagulation monitoring becomes essential to balance hemorrhagic risk against thrombotic risk.

References

Bettmann M . Anticoagulation and restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1987; 60(3):17B-19B. DOI: 10.1016/0002-9149(87)90478-4. View

Levine G, Bates E, Blankenship J, Bailey S, Bittl J, Cercek B . 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and.... J Am Coll Cardiol. 2011; 58(24):e44-122. DOI: 10.1016/j.jacc.2011.08.007. View

Camenzind E, Boersma E, Wijns W, Mauri L, Rademaker-Havinga T, Ordoubadi F . Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. Eur Heart J. 2014; 35(29):1932-48. DOI: 10.1093/eurheartj/ehu084. View

Yoshida K, Tanaka S, Sato Y, Watanabe K, Muramatsu K, Murakawa M . Global cerebral infarction after aortic arch replacement surgery in a patient with postoperatively revealed factor XII deficiency: a case report. J Med Case Rep. 2020; 14(1):150. PMC: 7488564. DOI: 10.1186/s13256-020-02470-1. View

Muikku O . Isosorbide dinitrate does not interfere with heparin anticoagulation: a placebo-controlled comparison with nitroglycerin in patients scheduled for coronary artery surgery. Acta Anaesthesiol Scand. 1994; 38(6):583-6. DOI: 10.1111/j.1399-6576.1994.tb03956.x. View

OGara P, Kushner F, Ascheim D, Casey Jr D, Chung M, de Lemos J . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012; 61(4):e78-e140. DOI: 10.1016/j.jacc.2012.11.019. View

Wolf P, DAgostino R, Kannel W, Bonita R, Belanger A . Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA. 1988; 259(7):1025-9. View

TAKAJO Y, Ikeda H, Haramaki N, Murohara T, Imaizumi T . Augmented oxidative stress of platelets in chronic smokers. Mechanisms of impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability. J Am Coll Cardiol. 2001; 38(5):1320-7. DOI: 10.1016/s0735-1097(01)01583-2. View

Baluwala I, Favaloro E, Pasalic L . Therapeutic monitoring of unfractionated heparin - trials and tribulations. Expert Rev Hematol. 2017; 10(7):595-605. DOI: 10.1080/17474086.2017.1345306. View

10.

Prescott E, Hippe M, Schnohr P, Hein H, Vestbo J . Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ. 1998; 316(7137):1043-7. PMC: 28505. DOI: 10.1136/bmj.316.7137.1043. View

11.

Lasne D, Bauters A, Le Querrec A, Bourdin C, Voisin S . [Guidelines for certification of Activated clotting time (ACT) according to the EN ISO 22870 standards]. Ann Biol Clin (Paris). 2015; 73(2):225-54. DOI: 10.1684/abc.2015.1035. View

12.

Olson J, Arkin C, Brandt J, Cunningham M, Giles A, KOEPKE J . College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998; 122(9):782-98. View

13.

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

14.

Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R . Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet. 2012; 380(9851):1396-405. DOI: 10.1016/S0140-6736(12)61336-1. View

15.

Ngozi S, Ernest N . Long-term smoking results in haemostatic dysfunction in chronic smokers. Niger Med J. 2014; 55(2):121-5. PMC: 4003713. DOI: 10.4103/0300-1652.129641. View

16.

Pomp E, Rosendaal F, Doggen C . Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol. 2007; 83(2):97-102. DOI: 10.1002/ajh.21059. View

17.

Severinsen M, Kristensen S, Johnsen S, Dethlefsen C, Tjonneland A, Overvad K . Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost. 2009; 7(8):1297-303. DOI: 10.1111/j.1538-7836.2009.03490.x. View

18.

Wannamethee S, Lowe G, Shaper A, Rumley A, Lennon L, Whincup P . Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J. 2005; 26(17):1765-73. DOI: 10.1093/eurheartj/ehi183. View

19.

Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M . Reversible reduction in plasma concentration of nitric oxide induced by cigarette smoking in young adults. Am J Cardiol. 1997; 79(11):1538-41. DOI: 10.1016/s0002-9149(97)00189-6. View

20.

Kornhuber K, Seidel H, Pujol C, Meierhofer C, Roschenthaler F, Pressler A . Hemostatic abnormalities in adult patients with Marfan syndrome. Cardiovasc Diagn Ther. 2019; 9(Suppl 2):S209-S220. PMC: 6837936. DOI: 10.21037/cdt.2019.08.09. View